Belite Bio, Inc (BLTE) Prices 6M ADS IPO at $6/ADS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFR
5. FFAI
6. TSLA
7. META
8. FICO
9. CART
10. LLY

Go back to Belite Bio, Inc (BLTE) Prices 6M ADS IPO at $6/ADS

Belite Bio Announces Pricing of $36 Million Initial Public Offering

April 28, 2022 6:59 PM EDT

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (Belite or the Company), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and metabolic diseases, today announced the pricing of its initial public offering of 6 million American Depositary Shares (ADSs) at a public offering price per ADS of $6.00. Each ADS represents one ordinary share of Belite. In addition, Belite has granted the underwriters a 30-day option to purchase an additional 900,000 ADSs at the initial public offering price, less the underwriting... More